Association between high expression of intratumoral fibroblast activation protein and survival in patients with intrahepatic cholangiocarcinoma.
Cancer-associated fibroblast
Fibroblast activation protein
Intrahepatic cholangiocarcinoma
Prognostic factor
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
11
04
2023
accepted:
24
10
2023
medline:
30
11
2023
pubmed:
29
11
2023
entrez:
28
11
2023
Statut:
epublish
Résumé
Cancer-associated fibroblasts (CAFs) have been reported to exhibit protumorigenic effects. Among the well-known CAF markers such as smooth muscle actin (SMA) and fibroblast activation protein (FAP), high expression of SMA in the peritumoral stroma has been reported to be a prognostic factor in various cancers. However, the effect of high FAP expression in intrahepatic cholangiocarcinoma (IHCC) has not been fully clarified. We evaluated the expression of CAF markers, focusing on FAP expression in the peripheral and intratumoral regions, to clarify the association with survival in patients with IHCC. The study cohort comprised 37 patients who underwent curative resection for IHCC. The FAP expressions were evaluated in the peripheral and intratumoral regions of the resected tissues. Clinicopathological factors and survival outcomes were investigated between patients with high versus low FAP expression. Uni- and multivariate analyses were performed to identify the prognostic factors for overall survival and relapse-free survival. The median area percentages of FAP expression in the peripheral and intratumoral regions were 15.5% and 17.8%, respectively. High FAP expression in the intratumoral region was significantly associated with worse overall survival and disease-free survival than low FAP expression in the intratumoral region. Multivariate analysis identified high intratumoral FAP expression as a risk factor for worse overall survival (hazard ratio, 2.450; p = 0.049) and relapse-free survival (hazard ratio, 2.743; p = 0.034). High intratumoral FAP expression was associated with worse survival, suggesting that intratumoral FAP expression represents malignant progression in patients with IHCC.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer-associated fibroblasts (CAFs) have been reported to exhibit protumorigenic effects. Among the well-known CAF markers such as smooth muscle actin (SMA) and fibroblast activation protein (FAP), high expression of SMA in the peritumoral stroma has been reported to be a prognostic factor in various cancers. However, the effect of high FAP expression in intrahepatic cholangiocarcinoma (IHCC) has not been fully clarified. We evaluated the expression of CAF markers, focusing on FAP expression in the peripheral and intratumoral regions, to clarify the association with survival in patients with IHCC.
METHODS
METHODS
The study cohort comprised 37 patients who underwent curative resection for IHCC. The FAP expressions were evaluated in the peripheral and intratumoral regions of the resected tissues. Clinicopathological factors and survival outcomes were investigated between patients with high versus low FAP expression. Uni- and multivariate analyses were performed to identify the prognostic factors for overall survival and relapse-free survival.
RESULTS
RESULTS
The median area percentages of FAP expression in the peripheral and intratumoral regions were 15.5% and 17.8%, respectively. High FAP expression in the intratumoral region was significantly associated with worse overall survival and disease-free survival than low FAP expression in the intratumoral region. Multivariate analysis identified high intratumoral FAP expression as a risk factor for worse overall survival (hazard ratio, 2.450; p = 0.049) and relapse-free survival (hazard ratio, 2.743; p = 0.034).
CONCLUSIONS
CONCLUSIONS
High intratumoral FAP expression was associated with worse survival, suggesting that intratumoral FAP expression represents malignant progression in patients with IHCC.
Identifiants
pubmed: 38017374
doi: 10.1186/s12876-023-03012-x
pii: 10.1186/s12876-023-03012-x
pmc: PMC10683315
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
415Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 22fk0210103s0201
Organisme : Grant-in-Aid for Scientific Research
ID : 20K08957
Informations de copyright
© 2023. The Author(s).
Références
Neoplasia. 2019 Dec;21(12):1133-1142
pubmed: 31759251
Hepatology. 2021 Jan;73 Suppl 1:75-85
pubmed: 32500550
Cell Commun Signal. 2018 Sep 4;16(1):54
pubmed: 30180849
Liver Int. 2019 May;39 Suppl 1:63-78
pubmed: 30907492
Surgery. 2002 Jan;131(1 Suppl):S159-64
pubmed: 11821804
Cancer Cell. 2022 Jun 13;40(6):656-673.e7
pubmed: 35523176
BMC Cancer. 2020 Oct 27;20(1):1032
pubmed: 33109151
Cancer Discov. 2022 Feb;12(2):484-501
pubmed: 34548310
Curr Opin Gastroenterol. 2011 May;27(3):276-84
pubmed: 21297470
JCI Insight. 2018 Oct 18;3(20):
pubmed: 30333314
Anal Quant Cytol Histol. 2001 Aug;23(4):291-9
pubmed: 11531144
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61
pubmed: 7911242
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Oncogene. 2014 May 8;33(19):2423-31
pubmed: 23728338
Oncol Rep. 2020 Sep;44(3):838-848
pubmed: 32705221
Hepatology. 2013 Sep;58(3):1042-53
pubmed: 23505219
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Cancer Gene Ther. 2022 Dec;29(12):2001-2012
pubmed: 35948763
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Int J Oncol. 2021 Aug;59(2):
pubmed: 34195849
Oncol Rep. 2022 Apr;47(4):
pubmed: 35169858
Cancer Res. 2016 Jul 15;76(14):4124-35
pubmed: 27216177
Ann Surg Oncol. 2009 Sep;16(9):2555-64
pubmed: 19548033
Int J Oncol. 2022 Jun;60(6):
pubmed: 35514301
Hum Pathol. 2017 Jul;65:92-100
pubmed: 28457731
PLoS One. 2013 Aug 05;8(8):e71189
pubmed: 23940715
World J Surg Oncol. 2021 May 7;19(1):142
pubmed: 33962620
Cancer Discov. 2022 Jun 2;12(6):1580-1597
pubmed: 35348629
Gastroenterology. 2017 Jul;153(1):191-204.e16
pubmed: 28390866
Hepatology. 2022 Jan;75(1):28-42
pubmed: 34387870
Int J Cancer. 2008 Dec 1;123(11):2518-31
pubmed: 18767044
Pathol Oncol Res. 2019 Jan;25(1):369-376
pubmed: 29134462
J Cancer. 2018 Sep 7;9(18):3278-3286
pubmed: 30271487
Cancer Cell Int. 2022 Apr 18;22(1):153
pubmed: 35436935
Cancer Med. 2018 Sep;7(9):4665-4677
pubmed: 30062820
Front Oncol. 2020 Sep 23;10:1747
pubmed: 33072555
Hepatology. 1999 Jun;29(6):1768-78
pubmed: 10347120
Nat Commun. 2022 May 26;13(1):2945
pubmed: 35618735
Int J Mol Sci. 2017 Jan 24;18(2):
pubmed: 28125014